Nuno Gomes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nuno Gomes has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
Filomena Azevedo
Department of Dermatovenereology, Centro Hospitalar Universitário de São João EPE, Porto, Portugal
9 shared publications- Filomena Azevedo
Department of Dermatology and Venereology, São João Local Health Unit, Porto, Portugal
9 shared publications - Sofia Magina
Department of Dermatology and Venereology Sao Joao Local Health Unit (ULS) Porto Portugal
5 shared publications - Bárbara Vieira Granja
Department of Dermatology and Venereology Sao Joao Local Health Unit (ULS) Porto Portugal
4 shared publications Ana Marques
Department of Pathology, Centro Hospitalar Universitário de São João EPE, Porto, Portugal
3 shared publicationsAna Nogueira
Department of Dermatovenereology, Centro Hospitalar Universitário de São João EPE, Porto, Portugal
3 shared publications
Latest Publications
- 26 February 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (8) , 1772-1774
Folliculotropic Mycosis Fungoides in a Teenager Treated With re‐ PUVA and Photodynamic Therapy
- 26 February 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (8) , 1772-1774
Folliculotropic Mycosis Fungoides in a Teenager Treated With re‐ PUVA and Photodynamic Therapy
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Tildrakizumab in the Treatment of Palmoplantar Plaque Psoriasis—A Multicenter Real‐World Retrospective Study
Introduction: The palmoplantar region is a high‐impact area in psoriasis, with a particularly negative impact on patients’ quality of life. Tildrakizumab has shown efficacy, effectiveness, and safety in the treatment of moderate‐to‐severe plaque psoriasis but has limited evidence in high‐impact areas. The aim of this study was to retrospectively investigate the effectiveness of tildrakizumab in palmoplantar psoriasis. Methods: This was a multicentric, real‐world, retrospective study of patients with generalized psoriasis with palmoplantar involvement treated with tildrakizumab 100 mg. Patient data were collected from clinical records, and psoriasis severity was evaluated using the ppPASI, ppPASI < 3, and ppPASI < 1 as co‐primary endpoints and the PASI, PGA, BSA, and DLQI as secondary endpoints at baseline and at Weeks 28, 40, and 52 of treatment. Results: Eighteen patients were included. Mean PASI, BSA, and PGA scores showed a marked reduction from baseline (9.7 ± 6.2; 11.0 ± 7.0; 3.3 ± 0.7) to Week 28 (1.5 ± 1.3; 1.5 ± 1.5; 1.4 ± 1.1), with further improvement at Week 40 (0.9 ± 1.0; 0.9 ± 1.0; 0.9 ± 0.7) and stabilization at Week 52 (1.1 ± 2.2; 1.0 ± 1.6; 0.9 ± 1.1). DLQI scores also improved substantially from baseline (15.1 ± 3.9) to Week 28 (3.7 ± 5.4) and Week 40 (1.4 ± 2.4), with a slight increase between Week 40 and Week 52 (2.3 ± 4.3). Mean ppPASI improved from 15.4 ± 11.1 at baseline to 4.8 ± 12.0 at Week 28 and 1.2 ± 1.6 at Week 40, stabilizing at Week 52 (1.5 ± 2.7). The proportion of patients achieving absolute ppPASI < 3 and ppPASI < 1 increased consistently over time, reaching 61%, 77%, and 81% for ppPASI < 3 and 44%, 62%, and 75% for ppPASI < 1 at Weeks 28, 40, and 52, respectively. Conclusion: This study, one of the few with 52‐week real‐world data specifically in palmoplantar psoriasis, confirms that tildrakizumab is a valuable therapeutic option for the treatment of psoriasis in this location, providing effective disease control.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Open AccessTildrakizumab in the Treatment of Palmoplantar Plaque Psoriasis—A Multicenter Real‐World Retrospective Study
Introduction: The palmoplantar region is a high‐impact area in psoriasis, with a particularly negative impact on patients’ quality of life. Tildrakizumab has shown efficacy, effectiveness, and safety in the treatment of moderate‐to‐severe plaque psoriasis but has limited evidence in high‐impact areas. The aim of this study was to retrospectively investigate the effectiveness of tildrakizumab in palmoplantar psoriasis. Methods: This was a multicentric, real‐world, retrospective study of patients with generalized psoriasis with palmoplantar involvement treated with tildrakizumab 100 mg. Patient data were collected from clinical records, and psoriasis severity was evaluated using the ppPASI, ppPASI < 3, and ppPASI < 1 as co‐primary endpoints and the PASI, PGA, BSA, and DLQI as secondary endpoints at baseline and at Weeks 28, 40, and 52 of treatment. Results: Eighteen patients were included. Mean PASI, BSA, and PGA scores showed a marked reduction from baseline (9.7 ± 6.2; 11.0 ± 7.0; 3.3 ± 0.7) to Week 28 (1.5 ± 1.3; 1.5 ± 1.5; 1.4 ± 1.1), with further improvement at Week 40 (0.9 ± 1.0; 0.9 ± 1.0; 0.9 ± 0.7) and stabilization at Week 52 (1.1 ± 2.2; 1.0 ± 1.6; 0.9 ± 1.1). DLQI scores also improved substantially from baseline (15.1 ± 3.9) to Week 28 (3.7 ± 5.4) and Week 40 (1.4 ± 2.4), with a slight increase between Week 40 and Week 52 (2.3 ± 4.3). Mean ppPASI improved from 15.4 ± 11.1 at baseline to 4.8 ± 12.0 at Week 28 and 1.2 ± 1.6 at Week 40, stabilizing at Week 52 (1.5 ± 2.7). The proportion of patients achieving absolute ppPASI < 3 and ppPASI < 1 increased consistently over time, reaching 61%, 77%, and 81% for ppPASI < 3 and 44%, 62%, and 75% for ppPASI < 1 at Weeks 28, 40, and 52, respectively. Conclusion: This study, one of the few with 52‐week real‐world data specifically in palmoplantar psoriasis, confirms that tildrakizumab is a valuable therapeutic option for the treatment of psoriasis in this location, providing effective disease control.
- 30 October 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (5) , 739-759
Prevention and management of cutaneous immune‐related adverse events: EADV Task Force statement
Cancer immunotherapy, particularly immune checkpoint inhibitors (ICI), has revolutionized oncology treatment by leveraging the immune system to recognize and eliminate cancer cells. However, despite its efficacy, immunotherapy may induce immune‐related adverse events (irAEs), including dermatological events, that can range from mild rashes to severe life‐threatening conditions such as toxic epidermal necrolysis. This paper aims to explore and analyse the preventive measures for cutaneous irAEs (cirAEs). By identifying risk factors, recognizing early signs and implementing preventive strategies, healthcare professionals can significantly mitigate the severity of irAEs, thereby improving patient outcomes and quality of life.
- 30 October 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (5) , 739-759
Prevention and management of cutaneous immune‐related adverse events: EADV Task Force statement
Cancer immunotherapy, particularly immune checkpoint inhibitors (ICI), has revolutionized oncology treatment by leveraging the immune system to recognize and eliminate cancer cells. However, despite its efficacy, immunotherapy may induce immune‐related adverse events (irAEs), including dermatological events, that can range from mild rashes to severe life‐threatening conditions such as toxic epidermal necrolysis. This paper aims to explore and analyse the preventive measures for cutaneous irAEs (cirAEs). By identifying risk factors, recognizing early signs and implementing preventive strategies, healthcare professionals can significantly mitigate the severity of irAEs, thereby improving patient outcomes and quality of life.
- Open Access
- 1 July 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 99 (4) , 642-644
Pitiríase rubra pilar após vacinação contra COVID‐19: tratamento bem‐sucedido com ustequinumabe
- 1 July 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 99 (4) , 642-644
Open AccessPitiríase rubra pilar após vacinação contra COVID‐19: tratamento bem‐sucedido com ustequinumabe
- Open Access
- 22 April 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (4) , 642-644
Pityriasis rubra pilaris after COVID-19 vaccination: successful treatment with ustekinumab
- 22 April 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (4) , 642-644
Open AccessPityriasis rubra pilaris after COVID-19 vaccination: successful treatment with ustekinumab
- 20 December 2022
- Vol. 20 (6) , 466-468
Aseptic Pustulosis of the Folds Successfully Treated with Methotrexate.
An otherwise healthy 47-year-old woman presented with confluent pustular lesions on the scalp for 5 months and asymptomatic pustular lesions on the trunk and extremities for 2 weeks. She did not have systemic clinical manifestations and was treated with oral antifungals and antibiotics (amoxicillin, and clavulanic acid and flucloxacillin), with no effect. The lesions were unrelated to her menstrual cycle, and she had no history of dermatosis, including acne, psoriasis, or folliculitis. (SKINmed. 2022;20:466-468).
- 20 December 2022
- Vol. 20 (6) , 466-468
Aseptic Pustulosis of the Folds Successfully Treated with Methotrexate.
An otherwise healthy 47-year-old woman presented with confluent pustular lesions on the scalp for 5 months and asymptomatic pustular lesions on the trunk and extremities for 2 weeks. She did not have systemic clinical manifestations and was treated with oral antifungals and antibiotics (amoxicillin, and clavulanic acid and flucloxacillin), with no effect. The lesions were unrelated to her menstrual cycle, and she had no history of dermatosis, including acne, psoriasis, or folliculitis. (SKINmed. 2022;20:466-468).
- Open Access
- 1 September 2022
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 97 (5) , 689-690
Múltiplos papulonódulos indolores em menina de três anos
- 1 September 2022
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 97 (5) , 689-690
Open AccessMúltiplos papulonódulos indolores em menina de três anos
- Open Access
- 13 July 2022
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 97 (5) , 689-690
Multiple painless papulonodules in a 3-year-old girl: type A lymphomatoid papulosis
- 13 July 2022
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 97 (5) , 689-690
Open AccessMultiple painless papulonodules in a 3-year-old girl: type A lymphomatoid papulosis
- Open Access
- 1 July 2022
- Published by Medknow in Indian Journal of Dermatology
- Vol. 67 (4) , 458-459
Cryosurgery-Induced Pneumomediastinum in a Young Woman with Hidradenitis Suppurativa
- 1 July 2022
- Published by Medknow in Indian Journal of Dermatology
- Vol. 67 (4) , 458-459
Open AccessCryosurgery-Induced Pneumomediastinum in a Young Woman with Hidradenitis Suppurativa
- 30 June 2022
- Vol. 20 (3) , 228-230
Normolipemic Plane Xanthoma.
A 77-year-old man, otherwise healthy, presented with multiple symmetric yellowish patches in his axillary folds and abdomen that had evolved for 6 months (Figures 1 and 2). The lesions were initially confined to the axillary folds but have since disseminated during last 3 months. The patient was asymptomatic, and the physical examination was normal. Dermatoscopic evaluation of the yellowish patches showed a yellow homogeneous amorphous structure (Figure 3). (SKINmed. 2022;20:228-230).
- 30 June 2022
- Vol. 20 (3) , 228-230
Normolipemic Plane Xanthoma.
A 77-year-old man, otherwise healthy, presented with multiple symmetric yellowish patches in his axillary folds and abdomen that had evolved for 6 months (Figures 1 and 2). The lesions were initially confined to the axillary folds but have since disseminated during last 3 months. The patient was asymptomatic, and the physical examination was normal. Dermatoscopic evaluation of the yellowish patches showed a yellow homogeneous amorphous structure (Figure 3). (SKINmed. 2022;20:228-230).